鲁抗医药及控股子公司多项产品中选第十一批全国药品集采

Core Viewpoint - LuKang Pharmaceutical (600789.SH) and its subsidiary, Shandong Lukang Pharmaceutical Group Sait Company, have successfully won bids for several drugs in the recent centralized procurement process, indicating a positive development for the company's market position and revenue potential [1] Group 1 - The selected products include: Cefoperazone Sodium for Injection, Dapagliflozin Tablets, Adenosylcobalamin Capsules, and Mesobam Injection [1] - The total sales revenue for the selected products in 2024 is projected to be 405 million yuan [1]